
The pharmaceutical industry faces challenges in drug discovery due to high costs and long timelines, with AI being used to optimize compound identification and reduce development time. While AI can enhance hit identification and compound quality, it lacks the ability to reliably predict kinetics or developability, requiring lab validation. The demand for more data-rich technologies is growing, and current AI models struggle with data quality and bias, especially due to limited datasets and publication bias. Integrating lab systems is essential for AI to function effectively, and advancements in AI-driven drug discovery aim to accelerate breakthroughs while balancing cost and risk.
When we set out to talk to kids about artificial intelligence, we thought we knew what we’d hear. We expected some to tell us they were using it to cheat a little, the way Millennials and Gen Xers opened up CliffsNotes or programmed formulas into their TI-82s, and others to share inspiring ways they were…

Business and technology leaders need no convincing that the time of agentic AI is here. Organizations are rapidly adopting agents, and few executives doubt the technology’s potential to transform work. But many organizations find that realizing the desired return on investment (ROI) from AI hinges on having the right foundation, with inadequate infrastructure and data…

This is today’s edition of The Download, our weekday newsletter that provides a daily dose of what’s going on in the world of technology. These startups are chasing the next big thing in LLMs Nine years after Google researchers introduced the transformer, this family of neural networks has become the engine inside every major large…
